View Future GrowthCurative Biotechnology 過去の業績過去 基準チェック /06Curative Biotechnology は平均年間 30% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。36.2% です。主要情報29.98%収益成長率40.05%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605お知らせ • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.お知らせ • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.お知らせ • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unitお知らせ • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.お知らせ • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.お知らせ • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.お知らせ • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.お知らせ • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.収支内訳Curative Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CUBT 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 250-32031 Mar 250-42031 Dec 240-42031 Dec 230-62031 Dec 220-52230 Sep 220-62230 Jun 220-62231 Mar 220-194131 Dec 210-194130 Sep 210-228031 Mar 210-175031 Dec 200-55031 Mar 200100質の高い収益: CUBTは現在利益が出ていません。利益率の向上: CUBTは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CUBTは利益を出していないが、過去 5 年間で年間30%の割合で損失を削減してきた。成長の加速: CUBTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CUBTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: CUBTの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/24 01:23終値2026/06/24 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curative Biotechnology, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000
お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42
お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6
お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605
お知らせ • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
お知らせ • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.
お知らせ • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unit
お知らせ • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.
お知らせ • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.
お知らせ • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
お知らせ • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.
お知らせ • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.